Phase II study of TS-1+CPT-11+BV followed by TS-1+L-OHP+BV in unresectable advanced colorectal cancer with RAS mutation - Phase II study of IRIS+BV followed by SOX+BV in advanced colorectal cancer with RAS mutation

iigata Colorectal Cancer Study Group0 个研究点目标入组 50 人开始时间: 2014年9月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1)Presence of severe drug allergy 2)Pregnant patients 3)Active infection(>=38.0C) 4) Presence of severe complication(interstitial pneumonia or lung fibrosis, renal failure, liver failure, Poorly controlled diabetes mellitus poorly controlled hypertension 5) Remarkable ECG change or clinical heart disease (heart failure, AMI, angina) 6)Active gastric bleeding or gastric ulcer 7)Peripheral neuropathy 8)Severe diarrhea 9)Pleural effusion or ascites needed to treat 10)Gastrointestinal perforation in 6 months (without obstractive colorectal cancer) 11)Thromboembolism or cerebral infarction(without asymptomatic lacunar infarction ), pulmonary infraction, intestinal pneumonia 12)Operation within 28days (an exception of implanting central venous reservoir) 13)Congenital hemorrhagic diathesis or coagulopathy 14)Other active malignancies of DFS is within 5years (except for the case skin basal carcinoma and cervical cancer be cured or Stomach cancer, esophageal cancer, colorectal pM cancer that was confirmed cured by an endoscopic treatment) 15)Needed to dosage systemic steroid 16)Evaluated to be ineligible by a physician for other reasons 17)Hemoptysis( more than 2.5ml) 18)Contraindication of L-OHP ,CPT-11, BV , TS-1 19)Primary tumor with severe stenosis that an endoscope does not pass(Except for the case that constructed excision of the primary tumor or the artificial anus) 20)Peritoneum metastasis confirmed with an image.

发起方

iigata Colorectal Cancer Study Group